NCT02933580

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants

A Double-blind, Placebo-controlled, Randomized, Phase 1, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 20 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of JNJ-56136379 in healthy Japanese adult participants following oral administration of single doses from 25 milligram (mg) up to 600 mg, in fasted conditions.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JNJ-56136379	Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.
OTHER	Placebo	Participants will receive matching placebo tablets on Day 1.

Timeline

• Start date: 2016-10-12
• Primary completion: 2017-02-04
• Completion: 2017-02-04
• First posted: 2016-10-14
• Last updated: 2018-03-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study